Close Menu

NEW YORK – Quidel reported after the close of the market on Wednesday that its third quarter revenues rose 8 percent year over year, beating Wall Street estimates.

For the three months ended Sept. 30, revenues increased to $126.5 million from $117.4 million in Q3 2018, beating the average analyst expectation of $125.6 million. The increase was driven primarily by growth in the rapid immunoassay business.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.